AKBA - Akebia Ther
Akebia Ther Logo

AKBA - Akebia Ther

https://www.akebia.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.

52W High
$4.08
52W Low
$1.24
MA Status:
50D: Below 200D: Above
Beta (~1 neutral, <0.9 lower risk)
1.02
Valuation
Rich
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
26.88
EV/EBITDA (<8 favorable)
63.68
EV/Revenue (<3 favorable)
3.44
P/S (TTM) (<3 favorable)
3.85
P/B (<3 favorable)
26.86
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
3.56%
Institutions (25–75% balanced)
43.22%
Shares Outstanding
265,145,000
Float
259,800,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
203,733,000
Gross Profit (TTM)
169,548,000
EPS (TTM)
-0.18
Profit Margin (>10% good)
-0.18%
Operating Margin (TTM) (higher better)
0.23%
ROE (TTM) (>15% strong)
-5.53%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.43
Momentum
Bearish momentum
Value
-0.1357
Previous
-0.1396
Trend
Rising
Signal Cross
No cross
As of
Sep. 11, 2025